

14th Congress of the International Ocular Inflammation Society (IOIS)

sioje

& The 4th International Assembly of Ocular Inflammation Societies

## Fluocinolone acetonide implant (lluvien<sup>®</sup>) in Birdshot cystoid macular edema



Pedro Silva<sup>1</sup>, Pedro Simões<sup>1</sup>, Miguel Cordeiro<sup>1</sup>, Carolina Bruxelas<sup>1</sup>, Marta Guedes<sup>1</sup> 1 - Hospital Egas Moniz – CHLO Financial interests: none

**Background:** The development of cystoid macular edema (CME) in Birdshot chorioretinopathy (BSCR) occurs in up to 50% of patients and the mainstay of therapy are corticosteroids administered orally, by intravitreal injection or intravitreal implant.


Patients & Methods: The authors present 2 cases of BSCR with chronic CME treated with fluocionolone acetonide

implant (Iluvien®). Both cases were also under treatment with corticoid-sparing drugs.


**Results:** Both cases of BSCR presented with a chronic CME refractory to oral immunossupression.

**<u>Case1</u>**: After 6 dexamethasone implants (Ozurdex<sup>®</sup>), 3 in each eye, with a 6 month interval between each implant, the patient was treated with the fluocionolone acetonide implant (lluvien<sup>®</sup>) and catatact surgery in both eyes. The cataract development seemed to be secondary to previous treatment with intravitreal steroids.

<u>**Case2:</u>** The second patient was treated initially with 2 dexamethasone implants (Ozurdex<sup>®</sup>), also with a 6 month gap, in the left eye, and then with a fluocionolone acetonide implant (Iluvien<sup>®</sup>).</u>




<u>Therapy and Outcome:</u> In both cases, there was no recurrence of CME after 6 months of fluocionolone acetonide implant (Iluvien<sup>®</sup>).




## 200 µm

Figures case 1: OCT-SD one month after the fluocionolone acetonide implant (Iluvien®)



**Figures case 2**: OCT-SD one month after the fluocionolone acetonide implant (lluvien<sup>®</sup>).



Figures case 2: OCT-SD six months after the fluocionolone acetonide implant (lluvien®)

**Figures case 1:** OCT-SD six months after the fluocionolone acetonide implant (lluvien®)

## **Conclusions:** Treatment with intravitreal corticosteroid implants is effective in refractory CME associated to BSCR. The

fluocinolone acetonide implant may be as effective as the dexamethasone implant with less frequent injections